Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19

Abstract

Seven patients with low-grade non-Hodgkin's lymphoma were treated with a combination of a murine monoclonal antibody directed against the B-cell-specific antigen CD19 (CLB-CD10), given twice weekly, and continuous infusion of low-dose recombinant interleukin-2 (rIL-2). We demonstrated stable serum CLB-CD19 levels throughout the 12 weeks of treatment, and… (More)
DOI: 10.1007/BF01517234

Topics

10 Figures and Tables

Cite this paper

@article{Vlasveld1995TreatmentOL, title={Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19}, author={L Th Tom Vlasveld and Annemarie Hekman and Florry A. Vyth-Dreese and Cornelis J. M. Melief and Johan J. Sein and Arie C. Voordouw and Trees A. M. Dellemijn and Elaine M. Rankin}, journal={Cancer Immunology, Immunotherapy}, year={1995}, volume={40}, pages={37-47} }